TY - JOUR
T1 - Therapeutic guide for mTOuRing through the braided kidney cancer genomic river
AU - Voss, Martin H.
AU - Hsieh, James J.
N1 - Funding Information:
M.H. Voss reports receiving commercial research grants from Bristol-Myers Squibb and Pfizer; speakers bureau honoraria from Novartis; and is a consultant/advisory board member for Bayer, Calithera BioSciences, Exelixis, GlaxoSmithKline, Natera, and Novartis. J.J. Hsieh reports receiving commercial research grants from Cancer Genetics, Novartis, and Pfizer and is a consultant/advisory board member for Chugai Pharma, Eisai, and Novartis. No other potential conflicts of interest were disclosed. J.J. Hsieh is supported by the NIH under award number R01CA138505, The J. Randall and Kathleen L. MacDonald Kidney Cancer Research Fund, and The Jill and Jeffrey Weiss Kidney Cancer Research Fund.
Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/5/15
Y1 - 2016/5/15
N2 - mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/ phenotypes beyond genes in kidney cancer, like a braided river.
AB - mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/ phenotypes beyond genes in kidney cancer, like a braided river.
UR - http://www.scopus.com/inward/record.url?scp=84968756959&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-0035
DO - 10.1158/1078-0432.CCR-16-0035
M3 - Article
C2 - 26920890
AN - SCOPUS:84968756959
SN - 1078-0432
VL - 22
SP - 2320
EP - 2322
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -